Our Compounding

Therapeutic Category:

Phosphodiesterase-5 Enzyme Inhibitor

Key Ingredients:

Sildenafil-as (PAH) inhibits phosphodiesterase type 5 (PDE-5)in smooth muscles of pulmonary vasculature where PDE-5 is responsible for the degradation of cyclic guanosine monophosphate (cGMP). Increased cGMP concentration results in pulmonary vasculture relaxation; vasodilation in the pulmonary bed and the systemic circulation (to a lesser degree) may occur.

Formulation Strength:

Sildenafil Suspension 5mg/ml

Pediatric Oral:

• Treatment of persistent pulmonary arterial hypertension of new born (PPHN) refractory to treatment with inhaled nitric oxide; facilitation of weaning from nitric oxide(i.e to attenute rebound effects after discontinuing inhaled nitric oxide)
• Secondary pulmonary hypertension following cardiac surgery

Oral : May be administered without regard to meals; shake well prior to use.